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ABSTRACT

The present disclosure encompasses systems, and their methods of use, for detecting a target analyte. The systems include
a first and second oligonucleotide probe that associate
together to form a complex that binds to a target analyte; a
cleavable reporter molecule that binds to the complex; and
cleaving agent.
17 Claims, 8 Drawing Sheets
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BINARY PROBE SYSTEM FOR SENSITIVE
DETECTION OF TARGET ANALYTES

conjugation of an oligonucleotide with two organic dyes, a
fluorophore and a quencher. Moreover, at least one round of
HPLC purification is required to remove fluorescent impurities, which cause high background fluorescence and reduce
both the sensitivity and the dynamic range of the probe.
Taking into account that the analysis of each individual SNP
requires two molecular beacon probes (each complementary
to a specific allele), genotyping thousands of SNPs by
molecular beacon probes becomes expensive. Accordingly, a
binary approach for nucleic acid recognition (Kolpashchikov
D. M. (2005) J. Am. Chem. Soc. 127: 12442-12443; KolpashchikovD. M. (2006)J.Am. Chem. Soc., 128: 10625-10628;
Kolpashchikov D. M. (2007) Chembiochem. 8: 2039-2042;
Kolpashchikov D. M. (2008). J. Am. Chem. Soc. 130: 29342935; Gerasimova et al., (2010) Chembiochem 11: 811-817)
has been developed. In this approach two oligonucleotide
probes form short hybrids with the analyte and generate a
fluorescent signal upon tertiary complex formation. The
approach enables SNP genotyping at room temperature with
exceptional specificity.

CROSS REFERENCE TO RELATED
APPLICATION

5

This application claims priority to and benefit ofU.S. Provisional Patent Application Ser. No. 61/328,791, filed on Apr.
28, 2010, which is incorporated herein by reference in its
entirety.
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STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
This disclosure was made with government support under
NIH Grant No. R21 HG004060awarded by the U.S. National
Institutes of Health of the United States government. The
government has certain rights in the disclosure.

15

TECHNICAL FIELD

20

SUMMARY

The present disclosure is generally related to systems for
the detection of specific analytes using a binary probe and a
reporter oligonucleotide.
25

BACKGROUND
Real time assays for the detection of specific nucleic acids
are of great importance, since they enable instant detection of
specific RNA/DNA sequences without the need of separating
the probe-analyte hybrid from the unbound probe. Molecular
beacon probes are a novel tool for real-time nucleic acid
analysis (Tyagi & Kramer (1996) Nat. Biotechnol. 14: 303308; Marras et al., (2006) Clin. Chim. Acta. 363: 48-60;
Wang, eta!., (2009)Angew. Chem. Int. Ed. Engl. 48: 856-870;
Li et al., (2008) Biochem. Biophys. Res. Commun. 373: 457461; Venkatesan et al., (2008) Chem. Soc. Rev. 37: 648-663).
The traditional molecular beacon is a stem-loop folded
oligonucleotide with a fluorophore at the 5'-end and a
quencher at its 3'-end. Hybridization to a complementary
single-stranded DNA or RNA converts the molecular beacon
into the elongated conformation, in which the fluorophore is
remote from the quencher, resulting in high fluorescence. The
simplicity and elegance of molecular beacon design has made
this probe a popular tool for nucleic acid analysis and has
served as an inspiration for a number of related assays (see,
for example, Du et al., (2003) J. Am. Chem. Soc. 125: 40124013; Ye et al., (2004)J.Am. Chem. Soc. 126: 7740-7741; Liu
& Lu (2006)Methods Mal. Biol. 335: 275-288; Grossmann et
al., (2007)Angew. Chem. Int. Ed. Engl. 46: 5223-5225; Linet
al., (2008) Nucleic Acids Res. 36: e123).
Molecular beacon probes are extensively used in real-time
PCR assays (Whitman & Dunbar (2008) Recent Pat. DNA
Gene Seq. 2: 20-26) and for RNA monitoring in living cells
(Bao et al., (2009) Ann. Rev. Biomed. Eng. 11: 25-47; Tyagi.
S. (2009) Nat. Methods 6: 331-338). Importantly, the stemloop structure not only brings the fluorophore close to the
quencher but also improves the probe specificity. Molecular
beacon probes discriminate between two nucleic acid
sequences that differ by a single nucleotide in a wider temperature range than do linear hybridization probes (Bonnet et
al., (l999)Proc. Natl. Acad. Sci. USA. 96: 6171-6176). These
properties are of particular importance for single nucleotide
polymorphism (SNP) genotyping.
One factor that limits the application of molecular beacon
probes in SNP genotyping is their high synthetic cost. Chemical synthesis of a regular molecular beacon probe requires
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Briefly described, embodiments of this disclosure, among
others, encompass systems, and their methods of use, for
detecting a target analyte, wherein the system comprises: (a)
a first oligonucleotide probe comprising: (i) atthe 5'-terminus
thereof, a reporter oligonucleotide-binding arm having a
nucleotide sequence complementary to the nucleotide
sequence of a first region of a reporter oligonucleotide; and
(ii) at the 3'-terminus thereof, an analyte-binding arm having
a nucleotide sequence characterized as selectively binding to
a first region of a target analyte; (b) a second oligonucleotide
probe comprising: (i) at the 3'-terminus thereof, a reporter
oligonucleotide-binding arm having a nucleotide sequence
complementary to the nucleotide sequence of a second region
of a reporter oligonucleotide; and (ii) at the 5'-terminus
thereof, an analyte-binding arm having a nucleotide sequence
characterized as selectively binding to a second region of a
target analyte; (c) a reporter oligonucleotide comprising: (i) a
first region having a nucleotide sequence complementary to
the reporter oligonucleotide-binding arm of the first oligonucleotide probe; (ii) a second region having a nucleotide
sequence complementary to the reporter oligonucleotidebinding arm of the second oligonucleotide probe; (iii) a fluorophore and a quencher disposed on the reporter oligonucleotide whereby the fluorophore and quencher interact in the
absence of a target analyte to quench fluorescence generated
by the fluorophore; and (iv) a cleavable site disposed between
the fluorescent label and the quencher, wherein the cleavable
site is characterized as cleavable by a protein enzyme or a
region of the first or the second oligonucleotide probe; and (d)
an oligonucleotide-cleaving agent characterized as specifically cleaving the cleavable site of the reporter oligonucleotide.
In embodiments ofthis aspect of the system of the disclosure, the oligonucleotide-cleaving agent can be selected from
the group consisting of an enzyme, a ribozyme, and a deoxyribozyme, and the ribozyme, and a deoxyribozyme can be
optionally derived from a configuration of a region of the first
oligonucleotide probe, the second oligonucleotide probe, or
both the first and the second oligonucleotide probe.
In embodiments ofthis aspect of the system of the disclosure, the oligonucleotide-cleaving agent can be an enzyme
selected from the group consisting of: a restriction endonuclease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a
DNA glycosylase. In embodiments of this aspect of the sys-

US 8,859,266 B2
3

4

tern of the disclosure, the reporter oligonucleotide-binding
arm of at least one oligonucleotide probe can comprise a
nucleotide sequence configured as a deoxyribozyme oligonucleotide-cleaving agent capable of specifically cleaving a
site in the reporter oligonucleotide when the oligonucleotide
probe is hybridized to the reporter oligonucleotide and to a
target analyte.
At least one of the first oligonucleotide probe and the
second oligonucleotide probe can further comprise a linker
connecting the analyte-binding arm and the reporter oligonucleotide-binding arm of said oligonucleotide probe.
The reporter oligonucleotide can be a molecular beacon
characterized as having a stem-loop configuration in the
absence of a target analyte. In embodiments of this aspect of
the system of the disclosure, at least one of the fluorophore
and the quencher can be attached to the reporter oligonucleotide at the 5' or the 3' terminus thereof.
In embodiments ofthis aspect of the system of the disclosure, the system can further comprise a target analyte that
with the first and second oligonucleotide probes, and the
reporter oligonucleotide forms a quadripartite complex.
In embodiments ofthis aspect of the system of the disclosure, the nucleotide sequences of the analyte-binding arms of
the first and the second oligonucleotide probes can be independently selected to specifically bind to a target analyte
comprising a deoxyribonucleotide sequence, a ribonucleotide sequence, a double-stranded nucleic acid, a peptide, a
polypeptide, or a variant thereof.
The system of the disclosure, the system can further comprise a plurality of oligonucleotide probe pairs, each probe
pair comprising a first oligonucleotide probe and a second
oligonucleotide probe. The plurality of oligonucleotide probe
pairs can selectively bind to a plurality of sites of a single
target analyte or to a plurality of target analytes.
In embodiments ofthis aspect of the system of the disclosure, the first or the second oligonucleotide probe can be
tethered to a substrate and can be disposed on the substrate as
an array.
Another aspect of the disclosure encompasses embodiments of method of identifying a target nucleotide sequence
comprising the steps of: (i) obtaining a test sample; (ii) forming a reaction mix by combining the test sample with: (a) a
first oligonucleotide probe comprising: (i) at the 5'-terminus
thereof, a reporter oligonucleotide-binding arm having a
nucleotide sequence complementary to the nucleotide
sequence of a first region of a reporter oligonucleotide; and
(ii) at the 3'-terminus thereof, an analyte-binding arm having
a nucleotide sequence characterized as selectively binding to
a first region of a target analyte; (b) a second oligonucleotide
probe comprising: (i) at the 3'-terminus thereof, a reporter
oligonucleotide-binding arm having a nucleotide sequence
complementary to the nucleotide sequence of a second region
of a reporter oligonucleotide; and (ii) at the 5'-terminus
thereof, an analyte-binding arm having a nucleotide sequence
characterized as selectively binding to a second region of a
target analyte; (c) a reporter oligonucleotide comprising: (i) a
first region having a nucleotide sequence complementary to
the reporter oligonucleotide-binding arm of the first oligonucleotide probe; (ii) a second region having a nucleotide
sequence complementary to the reporter oligonucleotidebinding arm of the second oligonucleotide probe; (iii) a fluorophore and a quencher disposed on the reporter oligonucleotide whereby said fluorophore and quencher interact in the
absence of a target analyte to quench fluorescence generated
by the fluorophore; and (iv) a cleavable site disposed between
the fluorescent label and the quencher, wherein the cleavable
site is characterized as cleavable by a protein enzyme or a

region of the first or the secondoligonucleotide probe, and (d)
an oligonucleotide-cleaving agent characterized as specifically cleaving the cleavable site of the reporter oligonucleotide; under conditions suitable for the formation of a quadripartite complex between the analyte-binding arms of the
first and the second oligonucleotide probes, a target analyte in
the test sample, and the reporter oligonucleotide, thereby
exposing a cleavable site of the reporter oligonucleotide for
cleavage; (iii) allowing cleavage of a cleavable site of the
reporter oligonucleotide, thereby releasing the fluorophore,
the quencher, or both the fluorophore and the quencher, from
the complex; (iv) illuminating the reaction mix at a wavelength suitable for inducing a fluorescent emission by the
fluorophore; and (v) detecting the fluorescence emitted by the
fluorophore, thereby detecting the presence of the target analyte in the sample.
Yet another aspect of the disclosure encompasses embodiments of a kit comprising: (a) a first oligonucleotide probe
comprising: (i) at the 5'-terminus thereof, a reporter oligonucleotide-binding arm having a nucleotide sequence
complementary to the nucleotide sequence of a first region of
a reporter oligonucleotide; (ii) at the 3'-terminus thereof, an
analyte-binding arm having a nucleotide sequence characterized as selectively binding to a first region of a target analyte;
and (iii) optionally, a linker region covalently linking the
reporter oligonucleotide-binding arm and the analyte-binding arm; (b) a second oligonucleotide probe comprising: (i) at
the 3'-terminus thereof, a reporter oligonucleotide-binding
arm having a nucleotide sequence complementary to the
nucleotide sequence of a second region of a reporter oligonucleotide; (ii) at the 5'-terminus thereof, an analyte-binding
arm having a nucleotide sequence characterized as selectively
binding to a second region ofa target analyte; and (iii) optionally, a linker region covalently linking the reporter oligonucleotide-binding arm and the analyte-binding arm; (c) a
reporter oligonucleotide comprising: (i) a first region having
a nucleotide sequence complementary to the reporter oligonucleotide-binding arm of the first oligonucleotide probe; (ii)
a second region having a nucleotide sequence complementary to the reporteroligonucleotide-binding arm of the second
oligonucleotide probe; (iii) a fluorophore and a quencher
disposed on the reporter oligonucleotide whereby said fluorophore and quencher interact in the absence of a target analyte to quench fluorescence generated by the fluorophore; and
(iv) a cleavable site disposed between the fluorescent label
and the quencher, wherein the cleavable site is characterized
as cleavable by a protein enzyme or a region of the first or the
second oligonucleotide probe; or a plurality of oligonucleotide probe pairs, each probe pair comprising a first oligonucleotide probe and a second oligonucleotide probe,
wherein the plurality of oligonucleotide probe pairs selectively binds to a plurality of sites of a single target analyte or
to a plurality of target analytes, and wherein one oligonucleotide probe in each probe pair optionally is tethered to a
substrate, and optionally disposed on the substrate as an
array; (d) optionally, an oligonucleotide-cleaving agent characterized as specifically cleaving the cleavable site of the
reporter oligonucleotide; and (e) packaging and instructions
for the use of the kit to detect a target analyte in a test sample.
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Further aspects of the present disclosure will be more
readily appreciated upon review of the detailed description of
its various embodiments, described below, when taken in
conjunction with the accompanying drawings.
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FIG. 1 is a scheme illustrating an embodiment of EnzBDPl.
FIG. 2 is a graph showing the fluorescence enhancement of
Enz-BDPl together with RNase HII in the presence C•) or in
the absence (0) of the analyte HepC30 (SEQ ID NO.: 1).
FIG. 3 is a scheme illustrating an embodiment of EnzBDP2.
FIG. 4 is a graph showing the fluorescence enhancement of
Enz-BDP2 in the presence of the analyte HepC40 (SEQ ID
NO.: 5) with C•) or without (0) RNase HII.
FIG. 5 is a graph showing the fluorescence enhancement of
Enz-BDP2 in the presence of the analyte HepC40 (SEQ ID
NO.: 5) as a function of the analyte concentration.
FIG. 6 is a scheme showing an RNase HU-based probe
assay. A ribonucleotide inserted in the reporter oligonucleotide is indicated as rA.
FIG. 7 is a scheme showing an endonuclease-based assay.
FIG. 8 is a scheme showing a flap structure-forming probe.
FIG. 9 is a scheme showing a glycosylase-based probe
assay. The damaged or mismatch-forming fluorophore-labeled nucleotide is indicated as VF.
FIG. 10 is a scheme showing microarrays of enzyme
assisted pro bes.
FIG. 11 is a scheme showing a deoxyribozyme-assisted
binary probe. One (strand~) or both reporteroligonucleotidebinding arms of the probe contain a deoxyribozyme
sequence. The deoxyribozyme cleaves the reporter oligonucleotide substrate in the quadripartite complex (Panel B). X
in the reporter oligonucleotide indicates the cleavage site.
FIG. 12 illustrates the quadripartite complex formed by the
binding of the Enz-MB2 strands a and~ (SEQ ID NOs.: 6 and
7, respectively; strand a italicized) to a target analyte (SEQ ID
NO.: 5) of the HepC40 virus and to a reporter oligonucleotide
(SEQ ID NO.: 8). Small case letters indicate ribonucleotides
in the reporter oligonucleotide (MB2).
FIG. 13 illustrates the quadripartite complex formed by the
binding of a and ~ strand oligonucleotide probes (SEQ ID
NOS.: 10 and 11, respectively) to a target analyte (SEQ ID
NO.: 9) of the HepC virus and to a reporter oligonucleotide
(SEQ ID NO.: 12). Each of the a and the~ strands includes a
region, the sequence of which forms a deoxyribozyme. In this
embodiment of a quadripartite complex, each of the strands
encodes a different deoxyribozyme and each is located opposite a cleavable ribonucleotide of the reporter oligonucleotide. Small case letters indicate ribonucleotides in the
reporter oligonucleotide.
The drawings are described in greater detail in the description and examples below.
The details of some exemplary embodiments of the methods and systems of the present disclosure are set forth in the
description below. Other features, objects, and advantages of
the disclosure will be apparent to one of skill in the art upon
examination of the following description, drawings,
examples and claims. It is intended that all such additional
systems, methods, features, and advantages be included
within this description, be within the scope of the present
disclosure, and be protected by the accompanying claims.

embodiments only, and is not intended to be limiting, since
the scope of the present disclosure will be limited only by the
appended claims.
Where a range of values is provided, it is understood that
each intervening value, to the tenth of the unit of the lower
limit unless the context clearly dictates otherwise, between
the upper and lower limit of that range and any other stated or
intervening value in that stated range, is encompassed within
the disclosure. The upper and lower limits of these smaller
ranges may independently be included in the smaller ranges
and are also encompassed within the disclosure, subject to
any specifically excluded limit in the stated range. Where the
stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in
the disclosure.
Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this disclosure
belongs. Although any methods and materials similar or
equivalent to those described herein can also be used in the
practice or testing of the present disclosure, the preferred
methods and materials are now described.
All publications and patents cited in this specification are
herein incorporated by reference as if each individual publication or patent were specifically and individually indicated
to be incorporated by reference and are incorporated herein
by reference to disclose and describe the methods and/or
materials in connection with which the publications are cited.
The citation of any publication is for its disclosure prior to the
filing date and should not be construed as an admission that
the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of
publication provided could be different from the actual publication dates that may need to be independently confirmed.
As will be apparent to those of skill in the art upon reading
this disclosure, each of the individual embodiments described
and illustrated herein has discrete components and features
which may be readily separated from or combined with the
features of any of the other several embodiments without
departing from the scope or spirit of the present disclosure.
Any recited method can be carried out in the order of events
recited or in any other order that is logically possible.
Embodiments of the present disclosure will employ, unless
otherwise indicated, techniques of medicine, organic chemistry, biochemistry, molecular biology, pharmacology, and
the like, which are within the skill of the art. Such techniques
are explained fully in the literature.
It must be noted that, as used in the specification and the
appended claims, the singular forms "a," "an," and "the"
include plural referents unless the context clearly dictates
otherwise. Thus, for example, reference to "a support"
includes a plurality of supports. In this specification and in the
claims that follow, reference will be made to a number of
terms that shall be defined to have the following meanings
unless a contrary intention is apparent.
As used herein, the following terms have the meanings
ascribed to them unless specified otherwise. In this disclosure, "comprises," "comprising," "containing" and "having"
and the like can have the meaning ascribed to them in U.S.
patent law and can mean "includes," "including," and the like;
"consisting essentially of' or "consists essentially" or the
like, when applied to methods and compositions encompassed by the present disclosure refers to compositions like
those disclosed herein, but which may contain additional
structural groups, composition components or method steps
(or analogs or derivatives thereof as discussed above). Such
additional structural groups, composition components or
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DETAILED DESCRIPTION
Before the present disclosure is described in greater detail,
it is to be understood that this disclosure is not limited to
particular embodiments described, and as such may, of
course, vary. It is also to be understood that the terminology
used herein is for the purpose of describing particular
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method steps, etc., however, do not materially affect the basic
and novel characteristic( s) of the compositions or methods,
compared to those of the corresponding compositions or
methods disclosed herein. "Consisting essentially of' or
"consists essentially" or the like, when applied to methods
and compositions encompassed by the present disclosure
have the meaning ascribed in U.S. patent law and the term is
open-ended, allowing for the presence of more than that
which is recited so long as basic or novel characteristics of
that which is recited is not changed by the presence of more
than that which is recited, but excludes prior art embodiments.
Prior to describing the various embodiments, the following
definitions are provided and should be used unless otherwise
indicated.

5-iodouracil, 5-ethyluracil, 5-propyluracil, 5-methoxyuracil,
5-hydroxymethyluracil, 5-(carboxyhydroxymethyl)uracil,
5-(methy laminomethyl )uracil, 5-(carboxymethy laminomethy l )-uracil, 2-thiouracil, 5-methyl-2-thiouracil, 5-(2-bromovinyl)uracil, uracil-5-oxyacetic acid, uracil-5-oxyacetic
acid methyl ester, pseudouracil, 1-methylpseudouracil, queosine, inosine, 1-methylinosine, hypoxanthine, xanthine,
2-aminopurine, 6-hydroxyaminopurine, 6-thiopurine, and
2,6-diaminopurine.
The term "hybridization" as used herein refers to the process of association of two nucleic acid strands to form an
anti-parallel duplex stabilized by means ofhydrogen bonding
between residues of the opposite nucleic acid strands. The
terms "hybridizing" and "binding", with respect to polynucleotides, are used interchangeably and is meant the formation of A-T and C-G base pairs between the nucleotide
sequence of a fragment of a segment of a polynucleotide and
a complementary nucleotide sequence of an oligonucleotide.
By complementary is meant that at the locus of each A, C, G
or T (or U in a ribonucleotide) in the fragment sequence, the
oligonucleotide sequenced has a T, G, C or A, respectively.
The hybridized fragment/oligonucleotide is called a
"duplex."
The terms "hybridizing specifically to" and "specific
hybridization" and "selectively hybridize to," as used herein
refer to the binding, duplexing, or hybridizing of a nucleic
acid molecule preferentially to a particular nucleotide
sequence under stringent conditions.
The terms "target" and "target analyte" as used herein refer
to an oligonucleotide, peptide or polypeptide for which it is
desired to detect. The target analyte for use in the methods
herein disclosed may be an isolated oligonucleotide, peptide
or polypeptide, an oligonucleotide, peptide or polypeptide
immobilized on a solid support, or in free solution. Altematively, the target oligonucleotide, peptide or polypeptide may
be on a cell surface, the cell being isolated from a plant or
animal host, a cultured cell or a cell or population of cells in
a tissue of a plant or animal.
The term "complementary" as used herein refers to a sufficient number in the oligonucleotide of complementary base
pairs in its sequence to interact specifically (hybridize) with
the target nucleic acid sequence to be amplified or detected.
As known to those skilled in the art, a very high degree of
complementarity is needed for specificity and sensitivity
involving hybridization, although it need not be 100%. Thus,
for example, an oligonucleotide that is identical in nucleotide
sequence to an oligonucleotide disclosed herein, except for
one base change or substitution, may function equivalently to
the disclosed oligonucleotides. A "complementary DNA" or
"cDNA" gene includes recombinant genes synthesized by
reverse transcription of messenger RNA ("mRNA").
By "immobilized on a solid support" is meant that an
oligonucleotide is attached to a substance at a particular location in such a manner that the system containing the immobilized fragment, primer or oligonucleotide may be subjected
to washing or other physical or chemical manipulation without being dislodged from that location. A number of solid
supports and means of immobilizing nucleotide-containing
molecules to them are known in the art; any of these supports
and means may be used in the methods of this disclosure.
The terms "probe" and "oligonucleotide probe" as used
herein refer to oligonucleotides nucleic acid sequences of
variable length used in the detection of identical, similar, or
complementary nucleic acid sequences by hybridization.
A "restriction enzyme" refers to an endonuclease (an
enzyme that cleaves phosphodiester bonds within a polynucleotide chain) that cleaves DNA in response to a recogni-
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DEFINITIONS
In describing and claiming the disclosed subject matter, the
following terminology will be used in accordance with the
definitions set forth below.
The terms "oligonucleotide" and "polynucleotide" as used
herein refer to any polyribonucleotide or polydeoxyribonucleotide that may be unmodified RNA or DNA or modified
RNA or DNA. Thus, for instance, polynucleotides as used
herein refers to, among others, single- and double-stranded
DNA, DNA that is a mixture of single- and double-stranded
regions, single- and double-stranded RNA, and RNA that is
mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be singlestranded or, more typically, double-stranded or a mixture of
single- and double-stranded regions. The terms "nucleic
acid," "nucleic acid sequence," or "oligonucleotide" also
encompass a polynucleotide as defined above.
The term "nucleotide" as used herein refers to a sub-unit of
a nucleic acid (whether DNA or RNA or an analogue thereof)
which may include, but is not limited to, a phosphate group,
a sugar group and a nitrogen containing base, as well as
analogs of such sub-units. Other groups (e.g., protecting
groups) can be attached to the sugar group and nitrogen
containing base group. It will be appreciated that, as used
herein, the terms "nucleotide" and "nucleoside" will include
those moieties which contain not only the naturally occurring
purine and pyrimidine bases, e.g., adenine (A), thymine (T),
cytosine (C), guanine (G), or uracil (U), but also modified
purine and pyrimidine bases and other heterocyclic bases
which have been modified (these moieties are sometimes
referred to herein, collectively, as "purine and pyrimidine
bases and analogs thereof'). Such modifications include, e.g.,
diaminopurine and its deravitives, inosine and its deravitives,
alkylated purines or pyrimidines, acylated purines or pyrimidines thiolated purines or pyrimidines, and the like, or the
addition of a protecting group such as acetyl, difluoroacetyl,
trifluoroacetyl, isobutyryl, benzoyl, 9-fluorenylmethoxycarbonyl, phenoxyacetyl, dimethylformamidine, N,N-diphenyl
carbamate, or the like. The purine or pyrimidine base may
also be an analog of the foregoing; suitable analogs will be
known to those skilled in the art and are described in the
pertinent texts and literature. Common analogs include, but
are not limited to, 1-methyladenine, 2-methyladenine,
N 6-methy!adenine, N 6-isopenty!adenine, 2-methy lthio-N 6isopenty ladenine, N,N-dimethyladenine, 8-bromoadenine,
2-thiocytosine, 3-methylcytosine, 5-methylcytosine, 5-ethylcytosine, 4-acetylcytosine, 1-methylguanine, 2-methylguanine, 7-methylguanine, 2,2-dimethylguanine, 8-bromoguanine, 8-chloroguanine, 8-aminoguanine, 8-methylguanine,
8-thioguanine, 5-fluorouracil, 5-bromouracil, 5-chlorouracil,
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ti on site on the DNA. The recognition site (restriction site)
consists of a specific sequence of nucleotides typically about
4-8 nucleotides long.
The term "RNase HII" as used herein refers to Ribonuclease HII which is an endoribonuclease that preferentially
nicks 5' to a ribonucleotide within the context of a DNA
duplex. The enzyme leaves 5' phosphate and3' hydroxyl ends.
RNase HII will also nick at multiple sites along the RNA
portion of an Okazaki fragment.
The term "reporter oligonucleotide" as used herein refers
to an oligonucleotide having a fluorophore moiety and a
quencher moiety attached thereto. The term "molecular beacon" and "oligonucleotide molecular beacon" as used herein
refer to a form of a reporter oligonucleotide having a fluorophore- and quencher-labeled stem-loop structured oligodeoxyribonucleotide that is widely used for real-time detection
of specific RNA/DNA sequences. In the stem-loop conformation, a fluorophore is brought close to the quencher
enabling efficient fluorescent quenching. Hybridization to a
complementary DNA/RNA target switches the molecular
beacon conformation to elongated, which is accompanied by
the fluorescence increase.
The term "fluorophore" as used herein refers to any
reporter group whose presence can be detected by its light
absorbing or light emitting properties. For example, Cy5 is a
reactive water-soluble fluorescent dye of the cyanine dye
family. Cy5 is fluorescent in the red region (about 650 to
about 670 nm). It may be synthesized with reactive groups on
either one or both of the nitrogen side chains so that they can
be chemically linked to either nucleic acids or protein mo!ecules. Labeling is done for visualization and quantification
purposes. Cy5 is excited maximally at about 649 nm and
emits maximally at about 670 nm, in the far red part of the
spectrum; quantum yield is 0.28. FW=792. Suitable fluorophores (chromes) for the probes of the disclosure may be
selected from, but not intended to be limited to, fluorescein
isothiocyanate (FITC, green), cyanine dyes Cy2, Cy3, Cy3.5,
Cy5, Cy5 .5 Cy7, Cy7 .5 (ranging from green to near-infrared),
Texas Red, and the like. Derivatives of these dyes for use in
the embodiments of the disclosure may be, but are not limited
to, Cy dyes (Amersham Bioscience), Alexa Fluors (Molecular Probes Inc.,), HILYTE® Fluors (AnaSpec ), andDYLITE 0
Fluors (Pierce, Inc).
The term "aptamer" as used herein is an isolated nucleic
acid molecule that binds with high specificity and affinity to a
target, such as a protein. An aptamer is a three dimensional
structure held in certain conformation( s) that provides chemical contacts to specifically bind its given target. Although
aptamers are nucleic acid based molecules, there is a fundamental difference between aptamers and other nucleic acid
molecules such as genes and mRNA. In the latter, the nucleic
acid structure encodes information through its linear base
sequence and thus this sequence is of importance to the function of information storage. In complete contrast, aptamer
function, which is based upon the specific binding of a target
molecule, is not entirely dependent on a conserved linear base
sequence (a non-coding sequence), but rather a particular
secondary/tertiary/ quaternary structure. Any coding potential
that an aptamer may possess is entirely fortuitous and plays
no role whatsoever in the binding of an aptamer to its cognate
target.
The terms "fluorescence quencher" or "quencher" as used
herein refer to a molecule that interferes with the fluorescence
emitted by a fluorophore. This quencher can be selected from
non-fluorescent aromatic molecules, to avoid parasitic emissions. Exemplary quenchers include, but are not limited to,
such as a Dabsyl or a BLACK HOLE QUENCHER® that are

nonfluorescent aromatic molecules that prevent the emission
of fluorescence when they are physically near a fluorophore.
The quencher can also be, but is not limited to, a fluorescent
molecule, for example TAMRA (carboxytetramethylrhodamine ). When the quencher is a fluorescent dye, its fluorescence wavelength is typically substantially different from
that of the reporter dye and the quencher fluorescence is
usually not monitored during an assay.
The terms "quench" or "quenches" or "quenching" or
"quenched" as used herein refer to reducing the signal produced by a molecule. It includes, but is not limited to, reducing the signal produced to zero or to below a detectable limit.
Hence, a given molecule can be "quenched" by, for example,
another molecule and still produce a detectable signal albeit
the size of the signal produced by the quenched molecule will
be smaller when the molecule is quenched than when the
molecule is not quenched.
The term "solid support" is used herein refers to any
insoluble and inert inorganic or organic material, preferably
having a large surface area to which surface organic molecules can be attached through bond formation or absorbed
through electronic or static interactions. Representative
examples of a "solid support" in context with the present
invention are silicates, such as Si0 2 resin, including, but not
limited to, ion-exchange resins, glass, dextranes, celluloses or
hydrophilic or hydrophobic polymers.
Further definitions are provided in context below. Unless
otherwise defined, all technical and scientific terms used
herein have the same meaning as commonly understood by
one of ordinary skill in the art of molecular biology. Although
methods and materials similar or equivalent to those
described herein can be used in the practice or testing of the
present disclosure, suitable methods and materials are
described herein.
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Generally, the assay system of the disclosure is composed
of two short synthetic oligonucleotide probes (stands a and ~
as shown, for example, in FIG. 1), a reporter oligonucleotide
labeled with both a fluorophore- and quencher (FIG. 1), and a
DNA processing enzyme, or a nucleic acid processing activity catalyzed by a region of at least one of the two oligonucleotide probes. Both strands a and ~ contain at least one nucleotide sequence region complementary to a region or regions
of the reporter oligonucleotide (reporter binding arms), and at
least one nucleotide sequence region complementary to at
least one region of the analyte (analyte binding arms). In the
presence of a target analyte such as, but not limited to, a
nucleic acid, strands a and ~' the reporter oligonucleotide,
and the analyte form a quadripartite complex. This complex
can be specifically recognized by a DNA processing enzyme,
a ribozyme, or deoxyribozyme (generated by the nucleotide
sequence and the conformation thereof of at least one of the
oligonucleotide probes) and which recognizes a specific site
in the reporter oligonucleotide and catalyzes a reaction cleaving the oligonucleotide and separation of two different molecules, each bearing the fluorophore or the quencher, but not
both, as (FIG. 1, right). The resultant increase in fluorescence
can be quantitatively detected by a conventional fluorimeter.
High specificity for a target analyte of the probe can be
predetermined by independent or semi-independent hybridization of the analyte-binding arms of stands a and ~ to the
analyte. Each arm can form a short hybrid with the analyte
that is sensitive to a minor variation such as single base
mispairing.
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It is contemplated that in certain embodiments, a single
dimensional configuration of the nucleotide sequence of one
of the two oligonucleotide probes. While it is contemplated
analyte molecule such as an oligonucleotide can accommodate several quadripartite complexes, each of which can be
that each of the oligonucleotide probes can independently
processed by enzyme cleavage to resulting in a fluorophore
form a ribozyme or a deoxyribozyme from the configuration
of the reporter oligonucleotide-binding arms, it is not within
and/or quencher release, thereby increasing sensitivity of the
assay, or able to detect a plurality of nucleotide sequence
the scope of the embodiments of the present disclosure forthe
variations within the single analyte molecule.
ribozyme or deoxyribozyme to result from interaction of the
two probes with each other.
The reporter oligonucleotide does not interact directly with
In the systems as encompassed by the present disclosure,
the analyte and is, therefore, independent of the analyte
sequence. Accordingly, it is possible to optimize the reporter 10 two oligonucleotide probes that can be made of DNA or RNA,
or a combination of both. Each strand of the DNA or RNA
oligonucleotide for use as a universal reporter not limited by
probe has a customized fragment that has sequence complethe nature of the target analyte. The reporter oligonucleotide
mentarity to a selected target analyte (the analyte-binding
can be costly to synthesize due to the attachment reactions to
link a fluorophore and the quencher to the beacon. A universal
arm), and a region having sequence complementarity to a
reporter can substantially reduce the cost of the multiplex 15 region of a reporter oligonucleotide such as, but not limited
to, a molecular beacon. The analyte-binding and reporterassay systems of the disclosure. Embodiments of the systems
binding arms optionally may be connected to each other by a
of the present disclosure are shown in Examples 1-9 below.
The desired oligonucleotide probes can be defined, synthelinker. It is further contemplated that the oligonucleotide
probes can have additional nucleotide sequences added to one
sized, and purified my methods well known in the art. Attachment of both a fluorophore and a fluorescence quencher to the 20 or both of the free ends of each strand of the probe and which
are complementary to, and can hybridize with, a region of the
universal reporter oligonucleotide are also well known in the
art.
respective strand to form a stem-loop structure. These addiEmbodiments of the present disclosure, therefore, encomtional stem-loop-forming sequences are termed structure stapass a PCR-free assay system that allows fluorescent detecbilization arms (SSA) (see below).
In the embodiments of the disclosure, it is contemplated
tion of specific target analytes, including, but not limited to, 25
specific nucleotide sequences, with high selectivity and senthat the two oligonucleotide probes may hybridize through
sitivity. The advantages of the assay over currently available
their respective analyte-binding arms with a target analyte.
approaches include, but are not limited to, discrimination of
While the targeted analyte can be advantageously a nucleic
signal nucleotide substitution in an analyzed nucleic acid
acid sequence, it is considered within the scope of the disclowith accuracy even at ambient temperatures, reduced detec- 30 sure for the analyte to be any biomolecule that may specifically bind to the analyte-binding arms of a pair of oligonucletion limits comparable to enzymatic amplification, and lower
otide probes, including, but not limited to, a peptide, a
costs per assay since only two short unmodified oligonuclepolypeptide, the glycosylated variants thereof, and the like,
otides are synthesized for each new analyte sequence, while
all other reagents are analyte independent and, therefore, can
wherein the analyte-binding arms may be an aptamer. Anabe obtained in bulk amount and utilized efficiently. In par- 35 lytes may be a component of, or isolated from a biological
ticular, the systems of the present disclosure provide an
source, including, but not limited to, a eukaryotic cell or
amplification of the detected fluorescent signal by allowing
tissue, a prokaryotic organism such as a bacterium or virus, or
repeated formation of quencher-dissociated fluorophores.
any other analyte to which the sequences of the pair of oligoThe systems of the present disclosure, accordingly, comnucleotides may specifically bind. Nucleic acid target anaprise two oligonucleotide probes, each probe comprising an 40 lytes can be, but are not limited to, a DNA strand, an RNA
analyte-binding arm, the nucleotide sequence of which may
strand, a nucleic acid double helix, and the like.
be selected to specifically bind to a target analyte, and a
The reporter oligonucleotide of the systems of the discloreporter oligonucleotide-binding arm, the sequence of which
sure comprises two nucleic acid sequences that can hybridize
to the reporter oligonucleotide-binding arms of a pair of olimay specifically bind to a region within the nucleotide
sequence of a reporter oligonucleotide. The systems of the 45 gonucleotide probes. Attached to the reporter oligonucleotide
present disclosure further comprise a reporter oligonucleare a fluorophore and a quencher. In the absence of binding to
the oligonucleotide probes, the reporter oligonucleotide prefotide having regions of nucleotide sequence complementary
to the sequences of the reporter oligonucleotide-binding arm
erentially assumes a configuration, such as a stem-loop strucof the oligonucleotide probes. The target analyte nucleotide
ture, where the fluorophore and the quencher are brought into
sequences (or regions of a peptide or polypeptide target ana- 50 close proximity, whereupon the quencher suppresses fluoreslyte) selected for binding to the analyte-binding arms of the
cence emission by the fluorophore if irradiated by incident
two oligonucleotide probes are chosen so as to place the two
excitor light.
In the systems provided by the disclosure, the reporter
probe molecules in sufficiently close to one another to allow
oligonucleotide may be, but is not limited to, a deoxyriboan interaction between the reporter-binding arms of both of
the probes and the complementary regions of the reporter 55 nucleic acid that may have a stem-loop conformation forming
oligonucleotide itself (and thereby generating a "binary
a molecular beacon. Although most molecular beacons are
probe").
DNA oligonucleotides, there is no technical obstacle to makThe reporter oligonucleotides of the disclosure also
ing molecular beacons that are RNA or chimeras of DNA and
RNA for use in the new binary RNA oligonucleotide probes.
include a fluorophore and a quencher moiety that may be
located at the extreme ends of the reporter oligonucleotide 60
In some embodiments, the reporter may include one or
molecule, or internally but separated such that ifthe reporter
more ribonucleotides that provide cleavable sites within the
oligonucleotide is elongated there is no interaction between
reporter nucleotide sequence. However, it is contemplated
the fluorophore and the quencher.
that the reporter oligonucleotide may comprise a nucleotide
In the embodiments of the present disclosure, the reporter
sequence that, when hybridized with a complementary
oligonucleotides further include at least one cleavable site 65 sequence in the reporter-binding-arm of an oligonucleotide
probe, forms a site that can be recognized and specifically
that may be specifically cleaved by a protein enzyme, or by a
ribozyme or a deoxyribozyme that is formed by the threecleaved by an enzyme.
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The probe can be customized for any fluorophore including, but not limited to, FAM, TAMRA, Dy 750, HEX™, JOE,
TET™, Texas Red-X, Alexa Fluor Dyes, Bodipy Dyes, CY
Dyes, Rhodanine, dyes, WellRED Dyes, MAX, and TEX
613; and for any quencher including, but not limited to, black
hole quenchers, Iowa Black Quenchers, and DABCYL. It is
within the scope of the disclosure, however, for a plurality of
systems to be combined, wherein a different target analyte is
detectable by each system and each system incorporates a
different and distinguishable fluorophore for the simultaneous detection of multiple analytes in a single test sample.
Reporter oligonucleotide-binding arms on each strand are
typically 3-20 nucleotides long, but routine experimentation
based on the reporter oligonucleotide will determine the optimum length.
For example, and not intended to be limiting, at least one
nucleotide sequence, when hybridized with a complementary
sequence in the reporter-binding-arm of an oligonucleotide
probe, forms a site that can be recognized and specifically
cleaved by a restriction endonuclease. In another embodiment, the nucleotide sequence, when hybridized with a
complementary sequence in the reporter-binding-arm of an
oligonucleotide probe, can form a site that includes a ribonucleotide and which can be specifically cleaved by RNase
HII. In all embodiments of the systems of the present disclosure, however, it is contemplated that the reporter oligonucleotide will have at least one cleavable site located between the
fluorophore and the quencher.
In the assays using the systems and methods of the present
disclosure, a test sample suspected of having a target analyte
is contacted with a pair of oligonucleotide probes having
analyte-binding arms that can specifically bind to the target
analyte, and which may then bind to the analyte under the
appropriate conditions. The reporter oligonucleotide-binding
arms of the bound oligonucleotide probes can then preferentially bind to the corresponding complementary regions
within the reporter oligonucleotide to form a quaternary, or
quadripartite, complex such as illustrated in FIGS. 1, 3, 6-11.
Initially, complexing of the reporter oligonucleotide with the
oligonucleotide probes will elongate the reporter oligonucleotide, thereby dissociating the fluorophore and the quencher
from each other and allowing, with a suitable wavelength of
incident light, to generate a first level of fluorescence emission intensity. However, by then providing the system with a
protein enzyme that specifically binds to, and cleaves, the
cleavable site(s) of the reporter oligonucleotide, a fragment(s) of the reporter oligonucleotide bearing the fluorophore (or quencher, or both the fluorophore and the quencher)
is released from the quadripartite complex, which then dissociates to reform with a new and uncleaved reporter oligonucleotide molecule to renew the cycle. Accordingly, the
detectable fluorescence intensity becomes amplified, providing increased sensitivity of the assay to the target analyte.
In one embodiment of the assay system of the disclosure,
however, the protein enzyme that can be used to specifically
cleave the reporter oligonucleotide can be replaced by at least
one of the reporter oligonucleotide-binding arms of the quadripartite complex assuming a configuration of a ribozyme (if
the oligonucleotide-binding arm is an RNA sequence) or a
deoxyribozyme (if the oligonucleotide-binding arm is an
RNA sequence) that can specifically cleave a site within the
reporter oligonucleotide sequence that includes a ribonucleotide, as illustrated in FIG. 11, for example.
For optimum selectivity, for example ofSNPs, the analytebinding arm of each strand of the probe ranges from about 6
to about 20 nucleotides in length, which makes the total
analyte fragment region recognizable by a pair of oligonucle-

otide probes about 12 to about 40 nucleotides long. The
analyte itself can be of any length from 12-40, to many thousand nucleotides. Analyte-binding arms of about 10 nucleotides are advantageous because a combined length of about
20 nucleotides of a target analyte will cover most unique
sequences in the genome. Analyte-binding arms that recognize an analyte region with a combined length longer than
about 20 nucleotides may have increased sensitivity.
Linkers
The analyte-binding- and reporter oligonucleotide-binding
arms of anoligonucleotideprobe of the systems of the present
disclosure may be, but not necessarily, separated by a linker.
For example, but not intended to be limiting, such a linker
may be a stretch of nucleotides. Such a linker may, when the
oligonucleotide probes are bound to a target analyte, hybridize to the linker of the second of the two pro bes bound to a
target analyte, whereupon the two linkers may hybridize to
form a double helix. However, it is also possible for the linker
to be merely one or two nucleotides that cannot form a duplex
double-helix, nor bind to the target analyte. It is further contemplated that the linker of an oligonucleotide probe may be,
but not limited to, a flexible triethylene glycol linker.
Also within the scope of the disclosure are systems where
one of the analyte-detecting oligonucleotide probes of a pair
of such probes is immobilized to a solid substrate. The present
disclosure therefore encompasses probes according to the
present disclosure that are immobilized on a solid or flexible
support, such as paper, nylon or other type of membrane,
filter, chip, glass slide, microchips, microbeads, or any other
such matrix, all of which are within the scope of this disclosure. The probe of this form is now called a "DNA chip".
These DNA chips can be used for analyzing the SNPs of the
present disclosure. The present disclosure further encompasses arrays or microarrays of nucleic acid molecules that
are based on one or more of the sequences described herein.
As used herein "arrays" or "microarrays" refers to an array of
distinct polynucleotides or oligonucleotides synthesized on a
solid or flexible support, such as paper, nylon or other type of
membrane, filter, chip, glass slide, or any other suitable solid
support. In one embodiment, the microarray is prepared and
used according to the methods and devices described in U.S.
Pat. Nos. 5,446,603; 5,545,531; 5,807,522; 5,837,832; 5,874,
219; 6,114,122; 6,238,910; 6,365,418; 6,410,229; 6,420,114;
6,432,696; 6,475,808 and 6,489,159 and PCT Publication
No. WO 01/45843 A2, the disclosures of which are incorporated by reference in their entireties.
Compositions and kits for the detection of analytes: The
oligonucleotide primers and probes of the present disclosure
have commercial applications in diagnostic kits for the detecti on of such as SNPs in biological specimens. A kit according
to the disclosure may comprise any of the oligonucleotide
primers or probes according to the disclosure and preferable
includes packaging and instructions for the use thereof. An
SNP detection kit may also include a lysing buffer for lysing
cells contained in the specimen.
One aspect of the disclosure, therefore, encompasses
embodiments of a system for detecting a target analyte, the
system comprising: (a) a first oligonucleotide probe comprising: (i) at the 5'-terminus thereof, a reporter oligonucleotidebinding arm having a nucleotide sequence complementary to
the nucleotide sequence of a first region of a reporter oligonucleotide; and (ii) at the 3'-terminus thereof, an analytebinding arm having a nucleotide sequence characterized as
selectively binding to a first region of a target analyte; (b) a
second oligonucleotide probe comprising: (i) at the 3'-terminus thereof, a reporter oligonucleotide-binding arm having a
nucleotide sequence complementary to the nucleotide
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sequence of a second region of a reporter oligonucleotide; and
(ii) at the 5'-terminus thereof, an analyte-binding arm having
a nucleotide sequence characterized as selectively binding to
a second region of a target analyte; (c) a reporter oligonucleotide comprising: (i) a first region having a nucleotide
sequence complementary to the reporter oligonucleotidebinding arm of the first oligonucleotide probe; (ii) a second
region having a nucleotide sequence complementary to the
reporter oligonucleotide-binding arm of the second oligonucleotide probe; (iii) a fluorophore and a quencher disposed
on the reporter oligonucleotide whereby the fluorophore and
quencher interact in the absence of a target analyte to quench
fluorescence generated by the fluorophore; and (iv) a cleavable site disposed between the fluorescent label and the
quencher, wherein the cleavable site is characterized as cleavable by a protein enzyme or a region of the first or the second
oligonucleotide probe; and (d) an oligonucleotide-cleaving
agent characterized as specifically cleaving the cleavable site
of the reporter oligonucleotide.
In embodiments ofthis aspect of the system of the disclosure, the oligonucleotide-cleaving agent can be selected from
the group consisting of an enzyme, a ribozyme, and a deoxyribozyme, and the ribozyme, and a deoxyribozyme can be
optionally derived from a configuration of a region of the first
oligonucleotide probe, the second oligonucleotide probe, or
both the first and the second oligonucleotide probe.
In embodiments ofthis aspect of the system of the disclosure, the cleavable site of the reporter oligonucleotide can
comprise a ribonucleotide.
In embodiments ofthis aspect of the system of the disclosure, the reporter oligonucleotide-binding arm of at least one
oligonucleotide probe can comprise a nucleotide sequence
that provides a site in the reporter oligonucleotide specifically
cleavable by a restriction endonuclease when said oligonucleotide probe is hybridized to the reporter oligonucleotide, and
the oligonucleotide-cleaving agent is said restriction endonuclease.
In embodiments ofthis aspect of the system of the disclosure, the oligonucleotide-cleaving agent can be an enzyme
selected from the group consisting of: a restriction endonuclease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a
DNA glycosylase.
In embodiments ofthis aspect of the system of the disclosure, the reporter oligonucleotide-binding arm of at least one
oligonucleotide probe can comprise a nucleotide sequence
configured as a deoxyribozyme oligonucleotide-cleaving
agent capable of specifically cleaving a site in the reporter
oligonucleotide when the oligonucleotide probe is hybridized
to the reporter oligonucleotide and to a target analyte.
In embodiments ofthis aspect of the system of the disclosure, the at least one of the first oligonucleotide probe and the
second oligonucleotide probe can further comprise a linker
connecting the analyte-binding arm and the reporter oligonucleotide-binding arm of said oligonucleotide probe.
In embodiments ofthis aspect of the system of the disclosure, the reporter oligonucleotide can be a molecular beacon
characterized as having a stem-loop configuration in the
absence of a target analyte.
In embodiments ofthis aspect of the system of the disclosure, at least one of the fluorophore and the quencher can be
attached to the reporter oligonucleotide at the 5' or the 3'
terminus thereof.
In embodiments ofthis aspect of the system of the disclosure, the system can further comprise a target analyte and
wherein the analyte, the first and second oligonucleotide
probes, and the reporter oligonucleotide form a quadripartite

complex, thereby providing a configuration of the cleavable
site of the reporter oligonucleotide allowing said site to be
cleaved.
In embodiments ofthis aspect of the system of the disclosure, the nucleotide sequences of the analyte-binding arms of
the first and the second oligonucleotide probes can be independently selected to specifically bind to a target analyte
comprising a deoxyribonucleotide sequence, a ribonucleotide sequence, a double-stranded nucleic acid, a peptide, a
polypeptide, or a variant thereof.
In embodiments ofthis aspect of the system of the disclosure, the first or the second oligonucleotide probe can be
tethered to a substrate.
In embodiments ofthis aspect of the system of the disclosure, the system can further comprise a plurality of oligonucleotide probe pairs, each probe pair comprising a first
oligonucleotide probe and a second oligonucleotide probe.
In embodiments ofthis aspect of the system of the disclosure, the plurality of oligonucleotide probe pairs can selectively bind to a plurality of sites of a single target analyte.
In embodiments ofthis aspect of the system of the disclosure, the plurality of oligonucleotide probe pairs can selectively bind to a plurality of target analytes.
In embodiments ofthis aspect of the system of the disclosure, one oligonucleotide probe in each probe pair can be
tethered to a substrate.
In embodiments ofthis aspect of the system of the disclosure, the oligonucleotide probe in each probe pair tethered to
a substrate can be disposed on the substrate as an array.
Another aspect of the disclosure encompasses embodiments of method of identifying a target nucleotide sequence
comprising the steps of: (i) obtaining a test sample; (ii) forming a reaction mix by combining the test sample with: (a) a
first oligonucleotide probe comprising: (i) at the 5'-terminus
thereof, a reporter oligonucleotide-binding arm having a
nucleotide sequence complementary to the nucleotide
sequence of a first region of a reporter oligonucleotide; and
(ii) at the 3'-terminus thereof, an analyte-binding arm having
a nucleotide sequence characterized as selectively binding to
a first region of a target analyte; (b) a second oligonucleotide
probe comprising: (i) at the 3'-terminus thereof, a reporter
oligonucleotide-binding arm having a nucleotide sequence
complementary to the nucleotide sequence of a second region
of a reporter oligonucleotide; and (ii) at the 5'-terminus
thereof, an analyte-binding arm having a nucleotide sequence
characterized as selectively binding to a second region of a
target analyte; (c) a reporter oligonucleotide comprising: (i) a
first region having a nucleotide sequence complementary to
the reporter oligonucleotide-binding arm of the first oligonucleotide probe; (ii) a second region having a nucleotide
sequence complementary to the reporter oligonucleotidebinding arm of the second oligonucleotide probe; (iii) a fluorophore and a quencher disposed on the reporter oligonucleotide whereby said fluorophore and quencher interact in the
absence of a target analyte to quench fluorescence generated
by the fluorophore; and (iv) a cleavable site disposed between
the fluorescent label and the quencher, wherein the cleavable
site is characterized as cleavable by a protein enzyme or a
region of the first or the secondoligonucleotide probe, and (d)
an oligonucleotide-cleaving agent characterized as specifically cleaving the cleavable site of the reporter oligonucleotide; under conditions suitable for the formation of a quadripartite complex between the analyte-binding arms of the
first and the second oligonucleotide probes, a target analyte in
the test sample, and the reporter oligonucleotide, thereby
exposing a cleavable site of the reporter oligonucleotide for
cleavage; (iii) allowing cleavage of a cleavable site of the
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reporter oligonucleotide, thereby releasing the fluorophore,
the quencher, or both the fluorophore and the quencher, from
the quadripartite complex; (iv) illuminating the reaction mix
at a wavelength suitable for inducing a fluorescent emission
by the fluorophore; and (v) detecting the fluorescence emitted
by the fluorophore, thereby detecting the presence of the
target analyte in the sample.
In embodiments ofthis aspect of the system of the disclosure, the oligonucleotide-cleaving agent can be selected from
the group consisting of an enzyme, a ribozyme, and a deoxyribozyme, and the ribozyme, and a deoxyribozyme can be
optionally derived from a configuration of a region of the first
oligonucleotide probe, the second oligonucleotide probe, or
both the first and the second oligonucleotide probe.
In embodiments ofthis aspect of the system of the disclosure, the cleavable site of the reporter oligonucleotide can
comprise a ribonucleotide.
In embodiments ofthis aspect of the system of the disclosure, the reporter oligonucleotide-binding arm of at least one
oligonucleotide probe can comprise a nucleotide sequence
that provides a site in the reporter oligonucleotide specifically
cleavable by a restriction endonuclease when said oligonucleotide probe is hybridized to the reporter oligonucleotide.
In embodiments ofthis aspect of the system of the disclosure, the cleavable site of the reporter oligonucleotide when in
the presence of a target analyte can be cleavable by an enzyme
selected from the group consisting of: a restriction endonuclease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a
DNA glycosylase.
In embodiments ofthis aspect of the system of the disclosure, the reporter oligonucleotide-binding arm of at least one
oligonucleotide probe can comprise a nucleotide sequence
configured as a deoxyribozyme capable of specifically cleaving a site in the reporter oligonucleotide when the oligonucleotide probe is hybridized to the reporter oligonucleotide and
to a target analyte.
In embodiments ofthis aspect of the system of the disclosure, the first oligonucleotide probe and the second oligonucleotide probe the analyte-binding arm and the reporter
oligonucleotide-binding arm thereof can be connected by a
linker.
In embodiments ofthis aspect of the system of the disclosure, the reporter oligonucleotide can be a molecular beacon
and can be characterized as having a stem-loop configuration
in the absence of a target analyte.
In embodiments ofthis aspect of the system of the disclosure, the at least one of the fluorophore and the quencher can
be attached to the reporter oligonucleotide at the 5' or the 3'
terminus thereof.
In embodiments ofthis aspect of the system of the disclosure, the method can further comprise a target analyte
wherein the analyte, the first and second oligonucleotide
probes, and the reporter oligonucleotide can form a quadripartite complex, thereby providing a configuration of the
cleavable site of the reporter oligonucleotide allowing said
site to be cleaved.
In embodiments ofthis aspect of the system of the disclosure, the nucleotide sequences of the analyte-binding arms of
the first and the second oligonucleotide probes can be independently selected to specifically bind to a target analyte
comprising a deoxyribonucleotide sequence, a ribonucleotide sequence, a double-stranded nucleic acid, a peptide, a
polypeptide, or a variant thereof.
In embodiments ofthis aspect of the system of the disclosure, the first or the second oligonucleotide probe can be
tethered to a substrate.

In embodiments ofthis aspect of the system of the disclosure, the method can comprise a plurality of oligonucleotide
probe pairs, each probe pair comprising a first oligonucleotide probe and a second oligonucleotide probe.
In embodiments ofthis aspect of the system of the disclosure, the plurality of oligonucleotide probe pairs can selectively bind to a plurality of sites of a single target analyte.
In embodiments ofthis aspect of the system of the disclosure, the plurality of oligonucleotide probe pairs can selectively bind to a plurality of target analytes.
In embodiments ofthis aspect of the system of the disclosure, one oligonucleotide probe in each probe pair can be
tethered to a substrate.
In embodiments ofthis aspect of the system of the disclosure, the oligonucleotide probe in each probe pair tethered to
a substrate can be disposed on the substrate as an array.
Yet another aspect of the disclosure encompasses embodiments of a kit comprising: (a) a first oligonucleotide probe
comprising: (i) at the 5'-terminus thereof, a reporter oligonucleotide-binding arm having a nucleotide sequence
complementary to the nucleotide sequence of a first region of
a reporter oligonucleotide; (ii) at the 3'-terminus thereof, an
analyte-binding arm having a nucleotide sequence characterized as selectively binding to a first region of a target analyte;
and (iii) optionally, a linker region covalently linking the
reporter oligonucleotide-binding arm and the analyte-binding arm; (b) a second oligonucleotide probe comprising: (i) at
the 3'-terminus thereof, a reporter oligonucleotide-binding
arm having a nucleotide sequence complementary to the
nucleotide sequence of a second region of a reporter oligonucleotide; (ii) at the 5'-terminus thereof, an analyte-binding
arm having a nucleotide sequence characterized as selectively
binding to a second region ofa target analyte; and (iii) optionally, a linker region covalently linking the reporter oligonucleotide-binding arm and the analyte-binding arm; (c) a
reporter oligonucleotide comprising: (i) a first region having
a nucleotide sequence complementary to the reporter oligonucleotide-binding arm of the first oligonucleotide probe; (ii)
a second region having a nucleotide sequence complementary to the reporteroligonucleotide-binding arm of the second
oligonucleotide probe; (iii) a fluorophore and a quencher
disposed on the reporter oligonucleotide whereby said fluorophore and quencher interact in the absence of a target analyte to quench fluorescence generated by the fluorophore; and
(iv) a cleavable site disposed between the fluorescent label
and the quencher, wherein the cleavable site is characterized
as cleavable by a protein enzyme or a region of the first or the
second oligonucleotide probe; or a plurality of oligonucleotide probe pairs, each probe pair comprising a first oligonucleotide probe and a second oligonucleotide probe,
wherein the plurality of oligonucleotide probe pairs selectively binds to a plurality of sites of a single target analyte or
to a plurality of target analytes, and wherein one oligonucleotide probe in each probe pair optionally is tethered to a
substrate, and optionally disposed on the substrate as an
array; (d) optionally, an oligonucleotide-cleaving agent characterized as specifically cleaving the cleavable site of the
reporter oligonucleotide; and (e) packaging and instructions
for the use of the kit to detect a target analyte in a test sample.
In embodiments ofthis aspect of the system of the disclosure, the oligonucleotide-cleaving agent can be selected from
the group consisting of an enzyme, a ribozyme, and a deoxyribozyme, and the ribozyme, and a deoxyribozyme are
optionally derived from a configuration of a region of the first
oligonucleotide probe, the second oligonucleotide probe, or
both the first and the second oligonucleotide probe.
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In embodiments ofthis aspect of the system of the disclomolecular beacon (molecular beacon-binding arm) and a
sure, the reporter oligonucleotide-binding arm of at least one
fragment complementary to a DNA analyte. In the presence
oligonucleotide probe can comprise a nucleotide sequence
of the analyte, the probe forms a quadripartite complex, in
configured as a deoxyribozyme capable of specifically cleavwhich BDP strands serve as adaptors to connect the analyte
ing a site in the reporter oligonucleotide when the oligonucleand the molecular beacon reporter. The molecular beaconotide probe is hybridized to the reporter oligonucleotide and
binding arm of BDP strand ~ is complementary to the
to a target analyte.
molecular beacon fragment, which contains a single riboIn embodiments ofthis aspect of the system of the disclonucleotide embedded into DNA sequence. RNase HII recogsure, the reporter oligonucleotide can be a molecular beacon
nizes the ribonucleotide-containing duplex fragment and
and is characterized as having a stem-loop configuration in 10 cleaves the phosphodiester bond at the 5'-end of the ribothe absence of a target analyte.
nucleotide. As a result, the molecular beacon is hydrolyzed
In embodiments ofthis aspect of the system of the disclointo two fragments, which dissociate from the quadripartite
sure, the oligonucleotide probe can be tethered to a substrate.
complex. The resulting tripartite complex of the analyte with
The specific examples below are to be construed as merely
two strands of Enz-BDPl can bind another molecule of
illustrative, and not !imitative of the remainder of the disclo- 15 molecular beacon from solution to form the complex, which
sure in any way whatsoever. Without further elaboration, it is
is then recognized by the enzyme. Therefore, the signal
believed that one skilled in the art can, based on the descripamplification is achieved.
tion herein, utilize the present disclosure to its fullest extent.
All publications recited herein are hereby incorporated by
TABLE 1
20
reference in their entirety.
The sequences of analyte HepC30 and
It should be emphasized that the embodiments of the
oligonucleotides constituting Enz-BDPl
present disclosure, particularly, any "preferred" embodiments, are merely possible examples of the implementations,
5'-TGCCCCGGAGGTCTGTAGACCGTGCACC-3'
HepC30
(SEQ ID NO. · 1)
merely set forth for a clear understanding of the principles of
the disclosure. Many variations and modifications may be 25
Enz-BDPl
5'-GACCATCTCAGACCTCCCGGG-3'
made to the above-described embodiment(s) of the disclosure
strand a
(SEQ ID NO.· 2)
without departing substantially from the spirit and principles
5'-CACGGTCTACGTTCCTATAG-3'
Enz-BDPl
of the disclosure. All such modifications and variations are
strand 13
(SEQ ID NO.· 3)
intended to be included herein within the scope of this dis30
closure, and the present disclosure and protected by the folMolecular
5'-F-CCGACTCACTAT~GGAAGAGATGGTCGG-Q-3'
lowing claims.
(SEQ ID NO.· 4)a
Beacon 1
(MBl)
The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
asmall case indicates ribonucleotide
description of how to perform the methods and use the compositions and compounds disclosed and claimed herein. 35 F and Q designate the Fluorescein and Black Hole 1 quencher,
Efforts have been made to ensure accuracy with respect to
respectively.
numbers (e.g., amounts, temperature, etc.), but some errors
Example 2
and deviations should be accounted for. Unless indicated
otherwise, parts are parts by weight, temperature is in ° C.,
and pressure is at or near atmospheric. Standard temperature 40
Referring now to FIG. 2, another embodiment of the disand pressure are defined as 20° C. and 1 atmosphere.
closure provides fluorescence enhancement of Enz-BDPl
It should be noted that ratios, concentrations, amounts, and
together with RNase HII in the presence or in the absence of
the analyte HepC30. Reaction conditions: 10 nM molecular
other numerical data may be expressed herein in a range
format. It is to be understood that such a range format is used
beacon 1, 100 nM strands a and~' 10 nM HepC30; 2U RNase
for convenience and brevity, and thus, should be interpreted in 45 HII; 20 mM Tris-HCI, pH 8.8; 10 mM (NH4 ) 2 S04 , 10 mM
KC!, 25 mM MgCI, 0.1 % Triton X-100; 30° C.
a flexible marmer to include not only the numerical values
explicitly recited as the limits of the range, but also to include
Example 3
all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and subReferring now to FIG. 3, another embodiment of the disrange is explicitly recited. To illustrate, a concentration range 50
closure provides a design ofEnz-BDP2. The probe consists of
of"about 0.1 % to about 5%" should be interpreted to include
a reporter oligonucleotide (in this example, but not limited
not only the explicitly recited concentration of about 0.1 wt%
thereto, a molecular beacon) and two DNA strands: strand a
to about 5 wt %, but also include individual concentrations
and strand~· Each of the strands contains a fragment comple(e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%,
1.1%,2.2%, 3.3%, and4.4%) within the indicated range. The 55 mentary to the reporter oligonucleotide (reporter oligonucleotide-binding arm) and a fragment complementary to a DNA
term "about" can include ±1 %, ±2%, ±3%, ±4%, ±5%, ±6%,
analyte. In the presence of the analyte, the probe forms a
±7%, ±8%, ±9%, or ±10%, or more of the numerical value(s)
quadripartite complex, in which BDP strands serve as adapbeing modified.
tors to connect the analyte and the reporter oligonucleotide.
EXAMPLES
60 Reporter oligonucleotide-binding arms of the BDP strands
are complementary to two reporter oligonucleotide fragExample 1
ments, each of which contains a single ribonucleotide embedded into DNA sequence. RNase HII recognizes the duplex
fragments and cleaves the phosphodiester bond at the 5' end
One embodiment of the system of the present disclosure
provides a molecular beacon (molecular beacon), which acts 65 of the ribonucleotide. As a result, reporter oligonucleotide is
hydrolyzed into three fragments-the fluorophore-containas a reporter, and two DNA strands: strand a and strand ~·
Each of the strands contains a fragment complementary to
ing fragment, the middle fragment, and the quencher-contain-
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ing fragment, which dissociate from the quadripartite complex. The resulting tripartite complex of the analyte with two
strands of Enz-BDP2 can bind another molecule of the
reporter oligonucleotide from solution to form the complex,
which is then recognized by the enzyme. Therefore, the signal
amplification is achieved.

reporter oligonucleotide in the absence of analyte, the
reporter oligonucleotide is only cleaved when the targeted
analyte is present and the oligonucleotide probes hybridize to
both the reporter oligonucleotide and the analyte to form the
quadripartite complex, followed by an increase in fluorescent
intensity.
Furthermore, the reporter oligonucleotide can form stemloop hairpin structure to minimize its interactions with
strands a and ~ in the absence of the analyte. This assay is
adoptable to microarray format as described below.

TABLE 2
The sequences of analyte HepC40
and oligonucleotides constituting Enz-BDP2
HepC40

TTCATCGTCTCGCCGCAGTACCACTGGTTTGTGCAAGAAT
(SEQ ID NO. · 5)

Enz-BDP2
strand a

GATCTATTGGTACTGCGGCGA
(SEQ ID NO.· 6)

Enz-BDP2
strand 13

GCACAAACCAGTGTATGTTAAC
(SEQ ID NO. · 7)

Molecular FAM-5'-CGCGTTAaCATACAAT~GATCGCG-BHQl
Beacon 2
(SEQ ID NO.· 8)a
(MB2)
asmall case indicates ribonucleotide

10

Example 6

15

20

Exonuclease-based assay: The reporter oligonucleotidecleaving enzyme can be an exonuclease that removes a 5' or
3'-end nucleotide. The reporter oligonucleotide will include a
fluorophore and/or a quencher on 3' or 5' ends. FIG. 7 schematically illustrates a fluorophore dye conjugated with either
3' or 5' of the reporteroligonucleotide. When the quadripartite
complex is formed (FIG. 7B) in the presence of the analyte, an
exonuclease can cleave off the fluorophore-conjugated nucleotide, resulting in an increase in fluorescence emission.
Furthermore, the reporter oligonucleotide can form stemloop hairpin structure to minimize its interactions with
strands a and ~ in the absence of the analyte. This assay is
adoptable to microarray format as described below.

As shown in FIG. 4, fluorescence enhancement of EnzBDP2 in the presence of the analyte HepC40 (SEQ ID NO.: 5) 25
with or without RNase HII. Reaction conditions: 10 nM
molecular beacon 2 (MB2), 100 nM BDP2 (strands a and~)
Example 7
10nMHepC40; 2URNaseHII; 20mMTris-HCI, pH 8.8; 10
mM (NH4 ) 2 S04 , 10 mM KC!, 25 mM MgCI, 0.1% Triton
30
X-100; 30° C.
Flap endonuclease-based assay: One of the oligonucleAs shown in FIG. 5, fluorescence enhancement of Enzotide probe strands (strand a in FIG. 8) can contain a stemBDP2 in the presence of the analyte HepC40 (SEQ ID NO.: 5)
loop structure resulting in the formation of an overhang strucas a function of the analyte concentration. Reaction conditure, a "flap structure", in quadripartite complex formed in the
tions: 10 nM universal molecular beacon 2 (MB2), 100 nM
presence of a target analyte (as shown in FIG. 8. Such a
BDP2 (strands a and~), 0.1-5 nM HepC40; 2U RNase HII; 35 structure is a specific substrate for Flap-endonuclease-1
(FEN-1) that cleaves a phosphodiester bond thereby liberat20mMTris-HCl,pH8.8; 10mM(NH4 ) 2 S04 , lOmMKCl,25
mM MgCI, 0.1 % Triton X-100; 30° C., for 1 h.
ing the fluorophore nucleotide.
Furthermore, the oligonucleotide molecular beacon can
Example 4
form stem-loop hairpin structure to minimize its interactions
40 with strands a and~ in the absence of the analyte. This assay
RNase H-based binary probe assay: In this embodiment of
is adoptable to microarray format as described below.
the assay, the reporter oligonucleotide molecular beacon conExample 8
tains one or more ribonucleotides between the fluorophore
and quencher attachment sites, as shown in FIGS. 6 and 12.
The quadripartite complex thus formed contains a DNA- 45
DNA glycosylase-based assay: In this assay the oligoRNA hybrid (circled) that is the substrate ofRNase HII. The
nucleotide molecular beacon has at least one irregular or
mismatched-forming nucleotide (indicated as VF in FIG. 9).
enzyme cleaves the reporter oligonucleotide substrate,
This nucleotide is conjugated with a fluorophore. The fluothereby releasing the fluorophore into solution. The single
rescence of the fluorophore is quenched by the closely located
stranded oligonucleotide molecular beacon cannot be cleaved
by RNase HII, which contributes to desirable low background 50 quencher moiety. Upon quadripartite complex formation,
fluorescence.
however, the double stranded fragment with the embedded
Furthermore, the oligonucleotide molecular beacon can
"damaged" nucleotide is recognized by a specific DNA glyform stem-loop hairpin structure to minimize its interactions
cosylase. Upon hydrolysis of the N-glucosidic bond (FIG. 9):
the fluorescently-labeled nucleotide base is released into
with strands a and~ in the absence of the analyte. This assay
55 solution. Possible glycosylases include, but are not limited to,
is adoptable to microarray format as described below.
uracil DNA glycosylases, 8-oxoguanine DNA glycosylase,
Example 5
3-methyadenine DNA glycosylas, T:G miss-pair DNA glycosylase, and the like.
Restriction endonuclease-based binary probe assay: This
Furthermore, the reporter oligonucleotide can form stemembodiment takes advantage of recognition and cleavage of 60 loop hairpin structure to minimize its interactions with
specific DNA sequences by restriction endonucleases. The
strands a and ~ in the absence of the analyte. This assay is
restriction site-forming sequences are included in the reporter
adoptable to microarray format as described below.
oligonucleotide and in the oligonucleotide-binding arm of
Example 9
strands a, ~'or both a and~· As shown in FIG. 3, more than
one such sequence can be included in the reporter oligonucle- 65
Microarrays of enzyme assisted binary probes: The sysotide. Since restriction endonucleases do not recognize single
stranded nucleic acid regions that would be present in the
tems of the disclosure can be adapted to the solid-support
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based formats such as microarrays. In microarrays, one of the
oligonucleotide probes can be attached to the surface of a
solid support, while a second strand and the analyte will be
added in solution, hybridized with the solid-support bound
strand, followed by treatment with a specific DNA processing
enzyme.
For example, as schematically shown in FIG. 10, a DNA
glycosylase-based assay according to Example 8 can be converted to the microarray format. FIG. 10 shows microarray
features, each of which contains covalently attached one
strand of the binary probe (strand a in FIG. 10). The analyte
and strand~ are incubated with the microarray in the presence
of the reporter oligonucleotide. The reporter oligonucleotide
contains damages or mismatch-forming nucleotide(s) conjugated with the quencher dye. When the quadripartite complex
is formed, the specific DNA glycosylase can be added to the
microarray and cleaves off the quencher conjugated bases.
The remaining quadripartite complex emits bright fluorescence, which can be detected by a conventional fluorescent
scanner.

Example 10

10

15

Deoxyribozyme assisted probe system: This type of probe
is related to enzyme-assisted probes, although the protein
enzyme is not required. The absence of a protein enzyme
reduces cost of the assay, and makes the assay system more
stable with a longer shelf-life.
In this embodiment of the probe system, at least one of the
oligonucleotide probes binding to the target analyte contains
a deoxyribozyme sequence embedded in the oligonucleotide
molecular beacon-binding arm.
Presence of the specific nucleic acid analyte results in the
formation of a quadripartite complex (FIG. 11) in which the
deoxyribozyme binds opposite the cleavable site (X) in the
reporter oligonucleotide. The cleavage of the reporter oligonucleotide leads to separation of fluorophore and the
quencher, thus generating high fluorescent signal. In the
example illustrated in FIG. 13, the two oligonucleotides of the
binary probe independently encode different deoxyribozymes.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 12
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 28
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, HepC30 fragment analyte

<400> SEQUENCE, 1
tgccccggag gtctgtagac cgtgcacc

<210>
<211>
<212>
<213>
<220>
<223>

28

SEQ ID NO 2
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Enz-BDPl strand alpha

<400> SEQUENCE, 2
gaccatctca gacctcccgg g

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 3
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Enz-BDPl strand beta

<400> SEQUENCE, 3
cacggtctac gttcctatag

<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>

SEQ ID NO 4
LENGTH, 28
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Molecular Beacon 1 (MBl) conjugated to
fluorescein and Black Hole Quencher 1 and N is ribonucleotide A
FEATURE,
NAME/KEY, misc_feature
LOCATION, (13) .. (13)
OTHER INFORMATION, n is ribonucleotide a

20
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26
-continued

<400> SEQUENCE, 4
ccgactcact atnggaagag atggtcgg

<210>
<211>
<212>
<213>
<220>
<223>

28

SEQ ID NO 5
LENGTH, 40
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, HepC40 fragment analyte

<400> SEQUENCE, 5
ttcatcgtct cgccgcagta ccactggttt gtgcaagaat

<210>
<211>
<212>
<213>
<220>
<223>

40

SEQ ID NO 6
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Enz-BDP2 strand alpha

<400> SEQUENCE,
gatctattgg tactgcggcg a

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 7
LENGTH, 22
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Enz-BDP2 strand beta

<400> SEQUENCE, 7
gcacaaacca gtgtatgtta ac

<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

22

SEQ ID NO 8
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Molecular beacon 2 (MB2) conjugated to
fluorescein and BHQ-1 (Nis ribonucleotide A)
FEATURE,
NAME/KEY, misc_feature
LOCATION, (8) .. (8)
OTHER INFORMATION, n is ribonucleotide a
FEATURE,
NAME/KEY, misc_feature
LOCATION, (17) .. (17)
OTHER INFORMATION, n is ribonucleotide a

<400> SEQUENCE, 8
cgcgttanca tacaatngat cgcg

<210>
<211>
<212>
<213>
<220>
<223>

24

SEQ ID NO 9
LENGTH, 42
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, HepC fragment analyte

<400> SEQUENCE, 9
cttttctatc ttcttgctgg ccctgttgtc ctgcatcacc gt

<210>
<211>
<212>
<213>

SEQ ID NO 10
LENGTH, 48
TYPE, DNA
ORGANISM, Artificial sequence

42
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28
-continued

<220> FEATURE,
<223> OTHER INFORMATION, strand alpha
<400> SEQUENCE, 10
gaccaggcta gctcaacgat ctcttcggcc agcaagaaga tagaaaag

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 11
LENGTH, 44
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, strand beta

<400> SEQUENCE, 11
acggtgatgc aggacaacag agggaggcta gctcaacgag agga

<210>
<211>
<212>
<213>
<220>
<223>

<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
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SEQ ID NO 12
LENGTH, 32
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Molecular Beacon conjugated to FAM and BHQl
(where in cnnc, nn are ribonucleotides gu, and in gnng, nn are
ribonucleotides au)
FEATURE,
NAME/KEY, misc_feature
LOCATION, (10) .. (11)
OTHER INFORMATION, nn is ribonucleotide pair gu;
FEATURE,
NAME/KEY, misc_feature
LOCATION, (24) .. (25)
OTHER INFORMATION, nn is ribonucleotide pair au;

<400> SEQUENCE, 12
cgcgtcctcn nccctgaaga gagnnggtcg cg

We claim:
1. A system for detecting a target analyte, the system com-
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label and the quencher, wherein the cleavable site is
characterized as cleavable by a protein enzyme; and
wherein the target analyte, the first and second oligonucle~~:
~
otide probes, and the reporter oligonucleotide form a
(a) a first oligonucleotide probe comprising: (i) at the 5'-terquadripartite complex, thereby providing a configuraminus thereof, a reporter oligonucleotide-binding arm
tion of the cleavable site of the reporter oligonucleotide
having a nucleotide sequence complementary to the
allowing said site to be cleaved by the protein enzyme.
nucleotide sequence of a first region of a reporter oligo2. The system of claim 1, wherein a cleavable site of the
nucleotide; and (ii) at the 3'-terminus thereof, an ana- 45 reporter oligonucleotide comprises a ribonucleotide.
lyte-binding arm having a nucleotide sequence charac3. The system of claim 1, wherein the reporter oligonucleterized as selectively binding to a first region of a target
otide-binding arm of at least one oligonucleotide probe comanalyte;
prises a nucleotide sequence that provides a site in the
(b) a second oligonucleotide probe comprising: (i) at the
reporter oligonucleotide specifically cleavable by a restric3'-terminus thereof, a reporter oligonucleotide-binding 50 ti on endonuclease when said oligonucleotide probe is hybridized to the reporter oligonucleotide, and the oligonucleotidearm having a nucleotide sequence complementary to the
nucleotide sequence of a second region of a reporter
cleaving agent is said restriction endonuclease.
4. The system of claim 1, wherein the protein enzyme is
oligonucleotide; and (ii) at the 5'-terminus thereof, an
selected from the group consisting of: a restriction endonuanalyte-binding arm having a nucleotide sequence characterized as selectively binding to a second region of a 55 clease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a
DNA glycosylase.
target analyte;
5. The system of claim 1, wherein at least one of the first
(c) a reporter oligonucleotide comprising: (i) a first region
oligonucleotide probe and the second oligonucleotide probe
having a nucleotide sequence complementary to the
further comprises a linker connecting the analyte-binding
reporter oligonucleotide-binding arm of the first oligonucleotide probe; (ii) a second region having a nucle- 60 arm and the reporter oligonucleotide-binding arm of said
otide sequence complementary to the reporter oligooligonucleotide probe.
nucleotide-binding arm of the second oligonucleotide
6. The system of claim 1, wherein the reporter oligonuclepro be; (iii) a fluorophore and a quencher disposed on the
otide is a molecular beacon characterized as having a stemloop configuration in the absence of a target analyte.
reporter oligonucleotide whereby said fluorophore and
quencher interact in the absence of a target analyte to 65
7. The system of claim 1, wherein at least one of the
quench fluorescence generated by the fluorophore; and
fluorophore and the quencher is attached to the reporter oligonucleotide at the 5' or the 3' terminus thereof.
(iv) a cleavable site disposed between the fluorescent
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8. The system of claim 1, wherein the nucleotide sequences

of the analyte-binding arms of the first and the second oligonucleotide probes are independently selected to specifically
bind to a target analyte comprising a deoxyribonucleotide
sequence, a ribonucleotide sequence, a double-stranded
nucleic acid, a peptide, a polypeptide, or a variant thereof.
9. The system of claim 1, wherein the first or the second
oligonucleotide probe is tethered to a substrate.
10. The system of claim 1, further comprising a plurality of
oligonucleotide probe pairs, each probe pair comprising a
first oligonucleotide probe and a second oligonucleotide
probe.
11. The system of claim 10, wherein one oligonucleotide
probe in each probe pair is tethered to a substrate.
12. The system of claim 11, wherein the oligonucleotide
probe in each probe pair of the plurality of oligonucleotide
probes is disposed on the substrate as an array.
13. A method of identifying a target analyte in a test
sample, the method comprising the steps of:
(i) forming a reaction mix by combining the test sample
with:
(a) a first oligonucleotide probe comprising: (i) at the
5'-terminus thereof, a reporter oligonucleotide-binding arm having a nucleotide sequence complementary
to the nucleotide sequence of a first region of a
reporter oligonucleotide; and (ii) at the 3'-terminus
thereof, an analyte-binding arm having a nucleotide
sequence characterized as selectively binding to a first
region of a target analyte;
(b) a second oligonucleotide probe comprising: (i) at the
3'-terminus thereof, a reporter oligonucleotide-binding arm having a nucleotide sequence complementary
to the nucleotide sequence of a second region of a
reporter oligonucleotide; and (ii) at the 5'-terminus
thereof, an analyte-binding arm having a nucleotide
sequence characterized as selectively binding to a
second region of a target analyte;
(c) a reporter oligonucleotide comprising: (i) a first
region having a nucleotide sequence complementary
to the reporter oligonucleotide-binding arm of the first
oligonucleotide probe; (ii) a second region having a
nucleotide sequence complementary to the reporter
oligonucleotide-binding arm of the second oligonucleotide probe; (iii) a fluorophore and a quencher
disposed on the reporter oligonucleotide whereby
said fluorophore and quencher interact in the absence
of a target analyte to quench fluorescence generated
by the fluorophore; and (iv) a cleavable site disposed
between the fluorescent label and the quencher,
wherein the cleavable site is characterized as cleavable by a protein enzyme or a region of the first, and
(ii) incubating the reaction mix under conditions suitable
for the formation of a quadripartite complex between the
analyte-binding arms of the first and the second oligonucleotide probes, the target analyte in the test sample,
and the reporter oligonucleotide, thereby exposing a
cleavable site of the reporter oligonucleotide for cleavage;
(iii) cleaving at the cleavable site of the reporter oligonucleotide with the protein enzyme, thereby releasing
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the fluorophore, the quencher, or both the fluorophore
and the quencher, from the quadripartite complex;
(iv) illuminating the reaction mix at a wavelength suitable
for inducing a fluorescent emission by the fluorophore;
and
(v) detecting the fluorescence emitted by the fluorophore,
thereby detecting the presence of the target analyte in the
test sample.
14. A kit comprising:
(a) a first oligonucleotide probe comprising: (i) at the 5'-terminus thereof, a reporter oligonucleotide-binding arm
having a nucleotide sequence complementary to the
nucleotide sequence of a first region of a reporter oligonucleotide; and (ii) at the 3'-terminus thereof, an analyte-binding arm having a nucleotide sequence characterized as selectively binding to a first region of a target
analyte;
(b) a second oligonucleotide probe comprising: (i) at the
3'-terminus thereof, a reporter oligonucleotide-binding
arm having a nucleotide sequence complementary to the
nucleotide sequence of a second region of a reporter
oligonucleotide; and (ii) at the 5'-terminus thereof, an
analyte-binding arm having a nucleotide sequence characterized as selectively binding to a second region of a
target analyte;
(c) a reporter oligonucleotide comprising: (i) a first region
having a nucleotide sequence complementary to the
reporter oligonucleotide-binding arm of the first oligonucleotide probe; (ii) a second region having a nucleotide sequence complementary to the reporter oligonucleotide-binding arm of the second oligonucleotide
probe; (iii) a fluorophore and a quencher disposed on the
reporter oligonucleotide whereby said fluorophore and
quencher interact in the absence of a target analyte to
quench fluorescence generated by the fluorophore; and
(iv) a cleavable site disposed between the fluorescent
label and the quencher, wherein the cleavable site is
characterized as cleavable by a protein enzyme, and
wherein one oligonucleotide probe in each probe pair
optionally is tethered to a substrate, and optionally disposed on the substrate as an array; wherein the target
analyte, the first and second oligonucleotide probes, and
the reporter oligonucleotide form a quadripartite complex, thereby providing a configuration of the cleavable
site of the reporter oligonucleotide allowing said site to
be cleaved by the protein enzyme; and
(d) optionally, packaging and instructions for the use of the
kit to detect a target analyte in a test sample.
15. The kit of claim 14, further comprising a plurality of
oligonucleotide probe pairs, each probe pair comprising a
first oligonucleotide probe and a second oligonucleotide
probe.
16. The kit of claim 15, wherein one oligonucleotide probe
in each probe pair is tethered to a substrate.
17. The kit of claim 16, wherein the oligonucleotide probe
in each probe pair of the plurality of oligonucleotide probes is
disposed on the substrate as an array.
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